Frankie Fang, founding managing partner of China-focused fund-of-funds Starquest Capital, discusses early-stage valuations, specialization among domestic managers, and renminbi fundraising
Q: How has your portfolio been impacted by COVID-19? A: We are focused on domestic consumption, healthcare, services, and technology that transforms traditional business. All these sectors have come...
Hangzhou-based drug developer Sumgen Biotech has raised RMB220 million ($32 million) in a Series B funding led by Addor Capital.
Increased climate change awareness on a corporate level is leading to more investment – either direct or through funds – in start-ups that offer mitigation solutions. Asia is a key geography
Healthcare-focused Panacea Venture has led a $40 million Series C round for China’s XWPharma, a neurobiology-focused biotech developer previously known as XW Laboratories.
Kyee Technology, a Chinese digital medical platform has raised RMB430 million ($64 million) in a Series D round led by Tencent Holdings. Other investors include Longmen Capital, Dyee Capital and Royal Sea Capital.